Vera Therapeutics(US:VERA) Globenewswire·2025-02-26 13:25Core Insights - Vera Therapeutics is advancing its investigational therapy atacicept for autoimmune diseases, particularly IgA nephropathy, with significant upcoming milestones including the announcement of primary endpoint results from the ORIGIN Phase 3 study in Q2 2025 and plans for a Biologics License Application (BLA) submission in the second half of 2025 [2][6][11] Business Highlights - For the fiscal year 2024, Vera reported a net loss of $152.1 million, or $2.75 per diluted share, compared to a net loss of $96.0 million, or $2.25 per diluted share, in 2023 [5][16] - Operating expenses for 2024 totaled $167.2 million, with research and development expenses at $126.2 million and general and administrative expenses at $41.0 million [16] - The company ended 2024 with $640.9 million in cash, cash equivalents, and marketable securities, which is expected to support operations through potential approval and commercial launch of atacicept [8][17] Upcoming Milestones - The primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA nephropathy is expected to be announced in Q2 2025, with a BLA submission planned for the second half of 2025 [6][10] - The ORIGIN Extend study has been initiated to provide participants with extended access to atacicept and gather longer-term safety and efficacy data [7] - A new QM dose-finding study is set to begin in 2025, and the PIONEER trial will evaluate atacicept in expanded IgA nephropathy populations [6][10] Financial Overview - Net cash used in operating activities for 2024 was $134.7 million, an increase from $92.2 million in the previous year [8] - The company completed two equity financings in 2024, raising approximately $593.2 million in net proceeds to strengthen its balance sheet [7] - As of December 31, 2024, total assets were reported at $655.7 million, with total liabilities at $78.5 million, resulting in stockholders' equity of $577.2 million [17]